Insulin Resistance Clinical Trial
Official title:
Fructose: Substrate, Stimulus, or Both?
This objective of this study is to use sensitive methodology under controlled conditions to investigate the mechanisms by which fructose consumption contributes to excess fatty acid synthesis and elevations in blood glucose levels following consumption of meals containing fructose.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | December 30, 2024 |
Est. primary completion date | June 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 55 Years |
Eligibility | Inclusion Criteria: - Body Mass Index 22 to 35 kg/m2 - Prediabetic (HbA1c 5.7% to 6.5%) or hyperinsulinemic (fasting insulin =12 µIU/mL) but non-diabetic (fasting glucose <126mg/dL and HbA1c < 6.5%) ; or normal control (fasting insulin <10 µIU/mL, fasting glucose <100 mg/dL, and HbA1c < 5.7%) Exclusion Criteria: - Pregnancy or lactation within the past six months - Type 1 or 2 diabetes mellitus - History of liver disease or aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2x the upper limit of normal (ULN); - Fasting triglyceride or total cholesterol levels above 95th percentile for age and sex; - Hemoglobin or hematocrit below the lower limit of normal for sex; - Report of hepatitis or HIV infection; - History of cancer, use of any anti-diabetic medications or hypolipidemic agents in the past six months; - History of surgical procedure for obesity; - Self-reported change in body weight >5% in the past six months; - History of other conditions known to affect insulin sensitivity and lipid metabolism; - Known intolerance to acetaminophen or components of the liquid test meals. |
Country | Name | City | State |
---|---|---|---|
United States | Touro University California | Vallejo | California |
Lead Sponsor | Collaborator |
---|---|
Touro University, California |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hepatic fractional de novo lipogenesis in triglyceride rich lipoprotein (TRL) | Measured by the detection of 13C carbons in TRL-palmitate from administered 13C labeled pyruvate or 13C labeled fructose. | 6 hours | |
Primary | Rate of appearance of UDP-glucose | An estimate of hepatic glycogen flux measured by administration of D1 galactose and acetaminophen | 6 hours | |
Primary | Rate of appearance of blood glucose from gluconeogenesis | Measured by the dilution method of labeled glucose | 6 hours | |
Secondary | Serum triglyceride concentration | Fasting and postprandial serum triglyceride levels | 6 hours | |
Secondary | Serum glucose concentration | Fasting and postprandial serum triglyceride levels | 6 hours | |
Secondary | Serum lactate concentration | Fasting and postprandial serum lactate levels | 6 hours | |
Secondary | Serum insulin concentration | Fasting and postprandial insulin levels | 6 hours | |
Secondary | Serum free fatty acid concentration | Fasting and postprandial fatty acid levels | 6 hours | |
Secondary | Enteral (chylomicron) fractional de novo lipogenesis (DNL) | Measured by the detection of 13C carbons in chylomicron-palmitate from administered 13C labeled pyruvate or 13C labeled fructose. | 6 hours | |
Secondary | Hepatic (VLDL) fractional de novo lipogenesis (DNL) | Measured by the detection of 13C carbons in VLDL-palmitate from administered 13C labeled pyruvate or 13C labeled fructose. | 6 hours | |
Secondary | Extrasplanchnic fructose | Calculated using total plasma fructose, plasma 2-13C fructose enrichment, and endogenous fructose production | 6 hours | |
Secondary | Whole body fructose oxidation | Measured by 13C atom % excess in exhaled breath, and VCO2 by indirect calorimetry | 6 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03142633 -
MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
|
||
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05354245 -
Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)
|
N/A | |
Completed |
NCT03383822 -
Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT04203238 -
Potato Research for Enhancing Metabolic Outcomes
|
N/A | |
Recruiting |
NCT03658564 -
Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance
|
N/A | |
Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03627104 -
Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A | |
Active, not recruiting |
NCT03288025 -
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
|
N/A | |
Completed |
NCT03809182 -
Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.
|
Phase 4 | |
Completed |
NCT01809288 -
Identifying Risk for Diabetes and Heart Disease in Women
|
||
Completed |
NCT04642482 -
Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity
|
Phase 4 | |
Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A | |
Withdrawn |
NCT04741204 -
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer
|
Phase 4 | |
Not yet recruiting |
NCT05540249 -
Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG
|
N/A |